2011

Every year without fail there are revelations about pharmaceutical companies behaving badly -- companies that have been charged with crimes such as making kickbacks to physicians, engaging in Medicare and Medicaid fraud, promoting products off label to physicians or companies that are called to testify before Congress about sub par manufacturing practices. 2010 seems to be unique in the number of companies behaving badly.

This is the last in a series of three articles highlighting points made by Kantar Health executives in a recent webinar titled, 'Getting It Right in the Emerging Markets: Identifying the opportunities and avoiding the pitfalls in conducting market research in new geographies.'

According to a recent CDC Data Brief, antidepressants were the third most common prescription drug taken by Americans of all ages in 2005–2008 and the most frequently used by persons aged 18–44 years. From 1988–1994 through 2005–2008, the rate of antidepressant use in the United States among all ages increased nearly 400%. Perhaps not so coincidentally, antidepressants are among the TOP advertised Rx category in 2010, according to the recent AdAge analysis.

Welcome to Volume 10, Issue #3 (17 FEBRUARY 2011) of Pharma Marketing News.

Welcome to Volume 10, Issue #11 (21 JUNE 2011) of Pharma Marketing News.

How many patients are needed these days to make a drug a billion dollar blockbuster? Less than you think. What are the implications for pharmaceutical marketing?

The long-awaited social media guidance from the FDA -- whenever it arrives -- may turn out to be nothing more than a stamp of approval on activities in which the industry is currently engaged. Practically every issue that FDA guidance is expected to address has already been handled independently by a few pioneering pharmaceutical companies. Rather than waiting for FDA's anti climatic guidelines, Pharmaguy decided to publish The Pharmaguy Social Media Timeline™ now, at a time when the industry already has set precedents in every social media application.

Were FDA's infamous 14 warning letters to pharma a ploy to force Google into a $500M DOJ settlement regarding illegal online pharmacy ads? In addition, could FDA have been holding back issuing pharma social media guidelines -- which would include guidelines for displayig compliant information in space-limited applications such as Twitter AND Google Adwords -- until Google settled its case with the DOJ?

The long-awaited social media guidance from the FDA -- whenever it arrives -- may turn out to be nothing more than a stamp of approval on activities in which the industry is currently engaged. Practically every issue that FDA guidance is expected to address has already been handled independently by a few pioneering pharmaceutical companies. Rather than waiting for FDA's anti climatic guidelines, Pharmaguy decided to publish The Pharmaguy Social Media Timeline™ now, at a time when the industry already has set precedents in every social media application.

David Epstein, head of Novartis Pharmaceuticals, said eighty percent of his company's sales reps will give up their PCs for iPads in 2012. Will they do it?